title: Value of electrophysiologic testing in patients with previous myocardial infarction and nonsustained ventricular tachycardia. Philadelphia Arrhythmia Group.
abstract: Previous studies of the value of electrophysiologic studies in patients with nonsustained ventricular tachycardia (VT) have been hampered by the inclusion of a small number of patients with various types of heart disease. This retrospective study was designed to assess the value of programmed stimulation in 205 asymptomatic patients who had had an acute myocardial infarction greater than 1 month before study. Inclusion was based on 24-hour Holter monitoring during which patients had to manifest greater than or equal to 3 consecutive ventricular beats at a rate greater than 135 beats/min. Forty-seven (23%) patients had normal, 70 (34%) mildly impaired and 88 (43%) severely impaired left ventricular function. Programmed stimulation, using up to 3 extrastimuli, was used in each. Seventy-five patients (36%) were noninducible, 59 (29%) had nonsustained VT (less than 30 seconds), 67 (33%) had sustained monomorphic VT and 4 (2%) had either polymorphic VT or ventricular fibrillation. Eighty-two patients were not treated with antiarrhythmic drugs, 57 others were placed on a program selected empirically and 66 had therapy guided by electrophysiologic testing. Satisfactory follow-up information was gathered in 187 of the 205 patients, with a mean follow-up of 18 months. One hundred forty-two patients are alive and well, 39 had sustained VT or sudden death and 6 others had a cardiac death. Only left ventricular function discriminated those who had a sustained arrhythmia or died from those who did not. Thus, programmed stimulation did not have independent predictive value in patients with nonsustained VT. However, definitive conclusions can be reached only with a large prospective study carried out in untreated patients.
authors.affiliation: Cardiology Division, Medical College of Pennsylvania, Philadelphia 19129.
authors.forename: P R
authors.initials: PR
authors.lastname: Kowey
authors.forename: H L
authors.initials: HL
authors.lastname: Waxman
authors.forename: A
authors.initials: A
authors.lastname: Greenspon
authors.forename: R
authors.initials: R
authors.lastname: Greenberg
authors.forename: D
authors.initials: D
authors.lastname: Poll
authors.forename: S
authors.initials: S
authors.lastname: Kutalek
authors.forename: L
authors.initials: L
authors.lastname: Gessman
authors.forename: L
authors.initials: L
authors.lastname: Muenz
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D015716:Electrocardiography, Ambulatory; D004594:Electrophysiology; D005260:Female; D005500:Follow-Up Studies; D006329:Heart Conduction System / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis*; D012189:Retrospective Studies; D013610:Tachycardia / Q000175:diagnosis* / Q000188:drug therapy; D013997:Time Factors
chemical_list: D000889:Anti-Arrhythmia Agents